Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dejanov

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Vascular Access|July 20, 2007
Are ambulatory femoral catheters for hemodialysis a safe vascular access?V Gerasimovska, A Oncevski, P Dejanov, et al.
The International Journal of Artificial Organs|June 21, 2002
Approach to vascular access for hemodialysis: experiences from the Republic of MacedoniaA Oncevski, P Dejanov, V Gerasimovska, et al.
Annales D'Urologie|January 6, 2001
[Vascular access and chronic renal failure]A Oncevski, P Dejanov, V Gerasimovska, et al.
Clinical Chemistry and Laboratory Medicine|August 17, 2001
Atherosclerosis risk factors related to hemodialysis duration and erythropoietin therapyB Dejanova, V Filipce, P Dejanov, et al.
Prilozi|March 1, 2005
[The role of the von Willebrand factor in renal diseases and haemodialysis patients]P Dejanov, M Polenaković, A Oncevski, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Vascular Access|July 20, 2007
Are ambulatory femoral catheters for hemodialysis a safe vascular access?V Gerasimovska, A Oncevski, P Dejanov, et al.
The International Journal of Artificial Organs|June 21, 2002
Approach to vascular access for hemodialysis: experiences from the Republic of MacedoniaA Oncevski, P Dejanov, V Gerasimovska, et al.
Annales D'Urologie|January 6, 2001
[Vascular access and chronic renal failure]A Oncevski, P Dejanov, V Gerasimovska, et al.
Clinical Chemistry and Laboratory Medicine|August 17, 2001
Atherosclerosis risk factors related to hemodialysis duration and erythropoietin therapyB Dejanova, V Filipce, P Dejanov, et al.
Prilozi|March 1, 2005
[The role of the von Willebrand factor in renal diseases and haemodialysis patients]P Dejanov, M Polenaković, A Oncevski, et al.
Pageof 1